386 related articles for article (PubMed ID: 26804544)
1. Biomarkers in bladder cancer: A metabolomic approach using in vitro and ex vivo model systems.
Rodrigues D; Jerónimo C; Henrique R; Belo L; de Lourdes Bastos M; de Pinho PG; Carvalho M
Int J Cancer; 2016 Jul; 139(2):256-68. PubMed ID: 26804544
[TBL] [Abstract][Full Text] [Related]
2. Discovery of urine biomarkers for bladder cancer via global metabolomics.
Shi H; Li X; Zhang Q; Yang H; Zhang X
Biomarkers; 2016 Nov; 21(7):578-88. PubMed ID: 27133288
[TBL] [Abstract][Full Text] [Related]
3. NMR-based metabolomic analysis of human bladder cancer.
Cao M; Zhao L; Chen H; Xue W; Lin D
Anal Sci; 2012; 28(5):451-6. PubMed ID: 22687923
[TBL] [Abstract][Full Text] [Related]
4. The development of plasma pseudotargeted GC-MS metabolic profiling and its application in bladder cancer.
Zhou Y; Song R; Zhang Z; Lu X; Zeng Z; Hu C; Liu X; Li Y; Hou J; Sun Y; Xu C; Xu G
Anal Bioanal Chem; 2016 Sep; 408(24):6741-9. PubMed ID: 27473428
[TBL] [Abstract][Full Text] [Related]
5. UPLC-MS based urine untargeted metabolomic analyses to differentiate bladder cancer from renal cell carcinoma.
Wang Z; Liu X; Liu X; Sun H; Guo Z; Zheng G; Zhang Y; Sun W
BMC Cancer; 2019 Dec; 19(1):1195. PubMed ID: 31805976
[TBL] [Abstract][Full Text] [Related]
6. Discovery and validation of potential urinary biomarkers for bladder cancer diagnosis using a pseudotargeted GC-MS metabolomics method.
Zhou Y; Song R; Ma C; Zhou L; Liu X; Yin P; Zhang Z; Sun Y; Xu C; Lu X; Xu G
Oncotarget; 2017 Mar; 8(13):20719-20728. PubMed ID: 28157703
[TBL] [Abstract][Full Text] [Related]
7. Renal cell carcinoma: a critical analysis of metabolomic biomarkers emerging from current model systems.
Rodrigues D; Monteiro M; Jerónimo C; Henrique R; Belo L; Bastos ML; Guedes de Pinho P; Carvalho M
Transl Res; 2017 Feb; 180():1-11. PubMed ID: 27546593
[TBL] [Abstract][Full Text] [Related]
8. Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery.
Liu X; Cheng X; Liu X; He L; Zhang W; Wang Y; Sun W; Ji Z
Int J Cancer; 2018 Jul; 143(2):408-418. PubMed ID: 29451296
[TBL] [Abstract][Full Text] [Related]
9. NMR-derived targeted serum metabolic biomarkers appraisal of bladder cancer: A pre- and post-operative evaluation.
Gupta A; Bansal N; Mitash N; Kumar D; Kumar M; Sankhwar SN; Mandhani A; Singh UP
J Pharm Biomed Anal; 2020 May; 183():113134. PubMed ID: 32070930
[TBL] [Abstract][Full Text] [Related]
10. Integrative Metabolomic and Transcriptomic Analysis for the Study of Bladder Cancer.
Loras A; Suárez-Cabrera C; Martínez-Bisbal MC; Quintás G; Paramio JM; Martínez-Máñez R; Gil S; Ruiz-Cerdá JL
Cancers (Basel); 2019 May; 11(5):. PubMed ID: 31100982
[TBL] [Abstract][Full Text] [Related]
11. Metabolomic and lipidomic approaches to identify biomarkers for bladder cancer and interstitial cystitis (Review).
Shahid M; Yeon A; Kim J
Mol Med Rep; 2020 Dec; 22(6):5003-5011. PubMed ID: 33174036
[TBL] [Abstract][Full Text] [Related]
12. Current Trends in Cancer Biomarker Discovery Using Urinary Metabolomics: Achievements and New Challenges.
Burton C; Ma Y
Curr Med Chem; 2019; 26(1):5-28. PubMed ID: 28914192
[TBL] [Abstract][Full Text] [Related]
13. Metabolomic Approaches for Detection and Identification of Biomarkers and Altered Pathways in Bladder Cancer.
di Meo NA; Loizzo D; Pandolfo SD; Autorino R; Ferro M; Porta C; Stella A; Bizzoca C; Vincenti L; Crocetto F; Tataru OS; Rutigliano M; Battaglia M; Ditonno P; Lucarelli G
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456991
[TBL] [Abstract][Full Text] [Related]
14. Metabolic Evaluation of Urine from Patients Diagnosed with High Grade (HG) Bladder Cancer by SPME-LC-MS Method.
Łuczykowski K; Warmuzińska N; Operacz S; Stryjak I; Bogusiewicz J; Jacyna J; Wawrzyniak R; Struck-Lewicka W; Markuszewski MJ; Bojko B
Molecules; 2021 Apr; 26(8):. PubMed ID: 33920347
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in the metabolomic study of bladder cancer.
Amara CS; Vantaku V; Lotan Y; Putluri N
Expert Rev Proteomics; 2019 Apr; 16(4):315-324. PubMed ID: 30773067
[TBL] [Abstract][Full Text] [Related]
16. Metabolite marker discovery for the detection of bladder cancer by comparative metabolomics.
Shao CH; Chen CL; Lin JY; Chen CJ; Fu SH; Chen YT; Chang YS; Yu JS; Tsui KH; Juo CG; Wu KP
Oncotarget; 2017 Jun; 8(24):38802-38810. PubMed ID: 28415579
[TBL] [Abstract][Full Text] [Related]
17. Metabolic Pathway Extension Approach for Metabolomic Biomarker Identification.
Wang L; Ye H; Sun D; Meng T; Cao L; Wu M; Zhao M; Wang Y; Chen B; Xu X; Wang G; Hao H
Anal Chem; 2017 Jan; 89(2):1229-1237. PubMed ID: 27983783
[TBL] [Abstract][Full Text] [Related]
18. Development of a universal metabolome-standard method for long-term LC-MS metabolome profiling and its application for bladder cancer urine-metabolite-biomarker discovery.
Peng J; Chen YT; Chen CL; Li L
Anal Chem; 2014 Jul; 86(13):6540-7. PubMed ID: 24877652
[TBL] [Abstract][Full Text] [Related]
19. Integrative Pathway Analysis of Metabolic Signature in Bladder Cancer: A Linkage to The Cancer Genome Atlas Project and Prediction of Survival.
von Rundstedt FC; Rajapakshe K; Ma J; Arnold JM; Gohlke J; Putluri V; Krishnapuram R; Piyarathna DB; Lotan Y; Gödde D; Roth S; Störkel S; Levitt JM; Michailidis G; Sreekumar A; Lerner SP; Coarfa C; Putluri N
J Urol; 2016 Jun; 195(6):1911-9. PubMed ID: 26802582
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
